Intelence, etravirine HIV Drug approved in US

US FDA approved Tibotec Therapeutics' Intelence, etravirine tablets for the treatment of HIV infection, to be used in combination with other anti-HIV medications, in adults who have failed treatment with other antiretrovirals.

Development of etravirine was triggered by the observations of in vitro anti-HIV activity of etravirine against mutant, NNRTI-resistant HIV strains.

"This is another significant new product for many HIV-infected patients who are NNRTI –resistant and whose infections are not responding to currently available medications," said Debra B. Birnkrant, M.D., director of the FDA's Division of Antiviral Products.

When used with other active anti-HIV medicines and when taken as prescribed, etravirine reduces the amount of HIV in the blood and increases white blood cells that help fight off other infections. In addition, etravirine may reduce the risk of death or infections that can occur with a weakened immune system.

The FDA's approval of etravirine is based primarily on data from 599 adults who received etravirine in two randomized, double-blind, placebo-controlled trials. After 24 weeks of treatment, more of the patients who received etravirine along with background therapy experienced reductions in the level of HIV in their blood than did those who received a placebo and background therapy.

The most common adverse events reported were rash and nausea. Patients developing a rash while taking etravirine should contact their doctor. To avoid drug interactions, patients starting etravirine treatment should tell their prescribers and pharmacists about all the medications they take. Information about drug interactions is contained in the etravirine package insert.

In the overall development program for etravirine, rare cases of serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme were reported. Patients taking etravirine may develop infections, including opportunistic infections or other conditions that may develop in patients living with HIV infection. The long-term effects of etravirine are not known, and its safety and effectiveness in children ages 16 years and younger has not been studied.

Etravirine also has not been studied in pregnant women. Women who are taking HIV medications when they become pregnant are advised to consult their physician or other health care professional about use of etravirine during pregnancy and about registering with the Antiviral Pregnancy Registry.

Etravirine is distributed by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., based in Bridgewater, N.J.

(Published at Health News Track on January 20, 2008 - 352 days ago)

HIV article/news source:

U.S. Food and Drug Administration - read other health news articles from U.S. Food and Drug Administration and health news articles from USA.

HIV - related articles/news stories:

- Circumcision reduces HIV risk in US men
- LUCAS cell phone to monitor HIV and malaria patients
- 109 medicines, vaccines in development for HIV AIDS
- £15 m for South Africa in new struggle against AIDS
- Routine HIV testing fails in US
- A man defeated HIV virus through bone marrow transplant
- TIM 3 protein turns off HIV fighting T cells
- HIV infected patients should start HAART sooner
- Estimating lives lost due to delay in HIV drug use in South Africa
- Antiretrovirals with TB treatment reduces mortality in HIV patients


»» Prodesse's ProFlu+ Test for Respiratory Viruses receives FDA clearance
«« Chromosomal abnormalities play substantial role in autism

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
We comply with the HONcode principles for trustworthy health information, verify here.
www.healthnewstrack.com - About us, Editorial team, Advertising, Jobs, Links, Privacy policy, Disclaimer, Feedback,
Site map, List health news, Health news organizations, Health news world, Accessibility, Glossary, Testimonials, Blog
Mobile/PDA Submit press release
© 2007-2008 HealthNewstrack.com
Track Health News Daily
3.41